Skip to main content
Premium Trial:

Request an Annual Quote

New Products: IBM and CLC Bio's Analysis Platform; Life Tech's Oncomine

Premium

IBM and CLC bio have launched an analysis platform that combines CLC bio's Genomics Server software and Genomics Workbench software with IBM hardware.

The companies are offering three versions for small, medium, and large analysis pipelines. The small configuration comes with 48 CPU cores and 192 GBs of memory, the medium version with 96 CPU cores and 396 GBs of memory, and the large version with 192 CPU cores and 768 GBs of memory.


Life Technologies' Ion Torrent has launched Oncomine Gene Browser and Ion Reporter Oncomine.

Oncomine Gene Browser enables researchers to characterize genes of interest across multiple parameters, including gene expression, DNA copy number, and mutation data, and is geared toward researchers working with small numbers of genes.

The Ion Reporter Oncomine workflow provides access to curated next-generation sequencing data from 4,000 matched tumor and normal pairs and is designed to assist with interpreting variants from data obtained on the Ion Torrent sequencing platforms. It will be available at no charge for an introductory period.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.